• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.

作者信息

Legg B, Rowland M

机构信息

Department of Pharmacy, University of Manchester, England.

出版信息

Pharm Res. 1988 Feb;5(2):80-5. doi: 10.1023/a:1015932032609.

DOI:10.1023/a:1015932032609
PMID:3073383
Abstract

Cyclosporin (CyA) exhibits saturable binding to erythrocytes. A one-site binding model was fitted to data from renal transplant patients receiving CyA therapy. The average maximum binding capacity is 2560 micrograms CyA/liter of packed erythrocytes; the unbound CyA concentration associated with 50% saturation of the binding site is 67 micrograms/liter. Analysis indicates that whole-blood CyA measurement to monitor drug therapy should be viewed cautiously, particularly when the hematocrit varies considerably. The error in estimating absolute bioavailability at steady state from whole-blood measurements, resulting as a consequence of the saturable binding, has been explored. Although extrapolation to the therapeutic situation, which involves transient drug administration, is difficult, errors of up to 25% are anticipated. When an accurate estimate of bioavailability is required, analysis based on plasma data is proposed. For bioequivalence testing, both blood and plasma CyA data are equally acceptable.

摘要

相似文献

1
Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.
Pharm Res. 1988 Feb;5(2):80-5. doi: 10.1023/a:1015932032609.
2
Cyclosporin: erythrocyte binding and an examination of its use to estimate unbound concentration.环孢素:红细胞结合及其用于估计游离浓度的研究。
Ther Drug Monit. 1988;10(1):16-9.
3
A model to account for the blood-to-plasma distribution of cyclosporin A in human blood.一种解释环孢素A在人血中血-浆分布的模型。
J Pharmacobiodyn. 1990 Jan;13(1):20-9. doi: 10.1248/bpb1978.13.20.
4
Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration.
Eur J Clin Pharmacol. 1988;34(5):451-60. doi: 10.1007/BF01046701.
5
Cyclosporin-erythromycin interaction in renal transplant patients.肾移植患者中环孢素与红霉素的相互作用。
Br J Clin Pharmacol. 1989 Apr;27(4):475-81. doi: 10.1111/j.1365-2125.1989.tb05396.x.
6
An optimized method for measuring cyclosporin A with 125I-labeled cyclosporin.一种用¹²⁵I标记的环孢素A测量环孢素A的优化方法。
Clin Chem. 1986 Jul;32(7):1378-82.
7
Cyclosporin: measurement of fraction unbound in plasma.环孢素:血浆中游离部分的测定
J Pharm Pharmacol. 1987 Aug;39(8):599-603. doi: 10.1111/j.2042-7158.1987.tb03436.x.
8
Relationship between apparent total body clearance of cyclosporin A and its erythrocyte-to-plasma distribution ratio in renal transplant patients.肾移植患者中环孢素A的表观全身清除率与其红细胞与血浆分布比之间的关系。
Biol Pharm Bull. 1995 Jan;18(1):115-21. doi: 10.1248/bpb.18.115.
9
Erythrocyte uptake and protein binding of cyclosporin A (CyA) in human blood: factors affecting CyA concentration in erythrocytes.环孢素A(CyA)在人血中的红细胞摄取及蛋白结合:影响红细胞中CyA浓度的因素
Biol Pharm Bull. 1993 Jul;16(7):702-7. doi: 10.1248/bpb.16.702.
10
Quantitative determination of cyclosporin A in whole blood and plasma by high performance liquid chromatography.
Res Commun Chem Pathol Pharmacol. 1987 Aug;57(2):261-71.

引用本文的文献

1
Analysis of the variable factors affecting changes in the blood concentration of cyclosporine before and after transfusion of red blood cell concentrate.浓缩红细胞输注前后影响环孢素血药浓度变化的可变因素分析。
J Pharm Health Care Sci. 2022 Feb 1;8(1):4. doi: 10.1186/s40780-021-00235-6.
2
Factors Affecting Time-Varying Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective.影响成人肾移植受者环孢素时变清除率的因素:群体药代动力学观点。
Pharm Res. 2021 Nov;38(11):1873-1887. doi: 10.1007/s11095-021-03114-9. Epub 2021 Nov 8.
3
Use of dried blood spots in drug development: pharmacokinetic considerations.

本文引用的文献

1
THE ESTIMATION OF HEPATIC BLOOD FLOW IN MAN.人体肝血流量的估计
J Clin Invest. 1945 Nov;24(6):890-7. doi: 10.1172/JCI101676.
2
A radioimmunoassay to measure cyclosporin A in plasma and serum samples.一种用于测量血浆和血清样本中环孢素A的放射免疫分析方法。
J Immunoassay. 1981;2(1):19-32. doi: 10.1080/01971528108062989.
3
Cyclosporin concentrations in whole blood and plasma.全血和血浆中环孢素的浓度。
干血斑在药物研发中的应用:药代动力学考量。
AAPS J. 2010 Sep;12(3):290-3. doi: 10.1208/s12248-010-9188-y. Epub 2010 Apr 10.
4
Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.亚洲肝移植患者全血和血浆中他克莫司的群体药代动力学
Clin Pharmacokinet. 2006;45(1):59-75. doi: 10.2165/00003088-200645010-00004.
5
Distribution of cyclosporin in organ transplant recipients.环孢素在器官移植受者体内的分布。
Clin Pharmacokinet. 2002;41(9):615-37. doi: 10.2165/00003088-200241090-00001.
6
The binding of cyclosporin A to human plasma: an in vitro microdialysis study.
Pharm Res. 1996 Apr;13(4):622-7. doi: 10.1023/a:1016066609489.
7
Cyclosporin clinical pharmacokinetics.环孢素的临床药代动力学。
Clin Pharmacokinet. 1993 Jun;24(6):472-95. doi: 10.2165/00003088-199324060-00004.
8
Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework.具有非线性结合的药物的广义药代动力学建模:I. 理论框架。
J Pharmacokinet Biopharm. 1993 Feb;21(1):99-124. doi: 10.1007/BF01061777.
9
Clinical pharmacokinetics in organ transplant patients.器官移植患者的临床药代动力学
Clin Pharmacokinet. 1989 Mar;16(3):134-61. doi: 10.2165/00003088-198916030-00002.
10
Cyclosporin-erythromycin interaction in renal transplant patients.肾移植患者中环孢素与红霉素的相互作用。
Br J Clin Pharmacol. 1989 Apr;27(4):475-81. doi: 10.1111/j.1365-2125.1989.tb05396.x.
Clin Chem. 1984 May;30(5):817.
4
Intravenous cyclosporine kinetics in renal failure.肾衰竭患者静脉注射环孢素的动力学
Clin Pharmacol Ther. 1983 Nov;34(5):638-43. doi: 10.1038/clpt.1983.226.
5
Therapeutic drug monitoring of cyclosporine.环孢素的治疗药物监测
Mayo Clin Proc. 1984 Aug;59(8):571-2. doi: 10.1016/s0025-6196(12)61496-7.
6
Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay.
Clin Chem. 1983 Jan;29(1):180-3.
7
Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites.环孢素在几种动物物种和人类中的处置。I. 其代谢产物的结构解析。
Drug Metab Dispos. 1984 Jan-Feb;12(1):120-6.
8
Measuring cyclosporin in plasma.测量血浆中的环孢素。
Lancet. 1983 Apr 2;1(8327):762. doi: 10.1016/s0140-6736(83)92046-9.
9
Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.脂蛋白和红细胞在环孢素A于血液中的体外结合及分布中的作用。
J Pharm Pharmacol. 1982 Nov;34(11):715-8. doi: 10.1111/j.2042-7158.1982.tb06206.x.
10
Clearance concepts in pharmacokinetics.药代动力学中的清除概念。
J Pharmacokinet Biopharm. 1973 Apr;1(2):123-36. doi: 10.1007/BF01059626.